BCL2 and mantle cell lymphoma: We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its combination with venetoclax, a BCL2 inhibitor.<h4>Methods</h4>A panel of nine MCL cell lines were used for in vitro experiments.